INTRODUCTION
Human parainfluenza virus type 1 (HPIV1) is an enveloped, negative-sense, ssRNA virus belonging to the genus Respirovirus of the family of Paramyxoviridae. Its genome is 15 600 nt long and consists of six genes, 3¢N-P/C-M-F-HN-L5¢ (Newman et al., 2002) . With the exception of the P/C gene, each gene contains a single ORF and encodes a single viral protein. The P/C gene of HPIV1 encodes a P protein from one ORF and up to four accessory C proteins (C¢, C, Y1 and Y2) from alternative, overlapping ORFs (Bartlett et al., 2008) . The viral particle is composed of a helical nucleocapsid which is packaged into a viral envelope originating from infected cells. Viral RNA with nucleoprotein (NP), phosphoprotein (P) and large (L) protein form the nucleocapsid, while glycosylated proteins haemagglutinin-neuraminidase (HN) and fusion (F) protrude from the viral envelope, and matrix (M) protein forms the inner layer of the envelope (Henrickson, 2003) .
HPIV1 causes upper and lower respiratory tract diseases in infants, young children and immunocompromised persons, who are frequently hospitalized because of the infection caused by this virus (Henrickson, 2003) . HPIV1 is most commonly associated with laryngotracheobronchitis (croup) and less with bronchiolitis and pneumonia. Epidemiological data suggest that HPIV infection occurred at least once for most young children and reinfection can occur throughout life (Henrickson, 2003; Moscona, 2005) .
Serotypes 1, 2 and 3 (HPIV1, 2 and 3) of human parainfluenza virus are the second leading causative agents of paediatric hospitalizations in the USA (Iwane et al., 2004; Morgan et al., 2013; Reed et al., 1997) and one of the five most common non-influenza causative agents of paediatric hospitalizations in Europe (Goka et al., 2015; Korsun et al., 2015; Pancer et al., 2014) . Although the incidence of hospitalization in the USA and Europe owing to HPIV-associated illness is 5.8-17 %, licensed vaccine or specific antiviral drugs are still not available (Takahashi et al., 2015) . Knowledge of the molecular epidemiology of HPIV1 gives insight into geographical and temporal circulation of its virus strains. This could provide data that would help in the development of an efficient protection (vaccine) and/or a specific HPIV1 therapy usable throughout the world and for a long period of time.
Although there are relatively numerous partial or complete genome sequences of HPIV1 in GenBank, only a few of them originate from Europe (viruses isolated in France 2007-2010, KF687314, KF687313 and KF687312) , and none of them originate from Eastern Europe.
Molecular epidemiological studies conducted in the past two decades in the USA (Beck et al., 2012) and Japan (Mizuta et al., 2011) determined co-circulation of HPIV1 divisible into three major genetic clusters/clades.
The goal of our study was to provide molecular characterization of HPIV1 viruses collected from patients hospitalized in Croatia during the three consecutive epidemic seasons: 2011-2012, 2012-2013 and 2013-2014 .
METHODS
Clinical samples Fifty-four clinical samples (nasopharyngeal secretions) collected from January 2011 to December 2014, which were positive in direct fluorescent antibody (DFA) method (DFA Light Diagnostics; Chemicon International) for HPIV1, were included in the study. All of the study samples were collected in the Zagreb region, from children hospitalized owing to acute respiratory tract infection, with age between 2 months and 7 years (Table 1) . Samples were stored in sterile minimal essential media at À20 C or À80 C. Thirty-one clinical samples were chosen for further molecular analysis based on their collection date and storage history. This study was approved by the Ethics Committees of the University Hospital for Infectious Diseases.
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RNA extraction, RT-nested PCR and sequencing Viral RNA was isolated from 250 µl of clinical sample as reported previously (Chomczynski & Mackey, 1988) . cDNA was prepared from total RNA using random hexamers and MuLV reverse transcriptase as reported previously (Košutić -Gulija et al., 2008) . Nested PCRs were performed for HN, F and P genes. For each gene, 10 µl of cDNA was amplified with OneTaq DNA Polymerase (New England Biolabs) in a 50 µl reaction mixture according to the manufacturer's instructions. Primer pairs for first round of PCR were as follows: HN gene F 6556 F and HN 8840 R, F gene F 4632 F and F 7012 R and P gene P 1651 F and P 3829 R. The cycling conditions for the first PCR were identical for three genes: denaturation at 95˚C for 5 min/10 cycles on 95˚C/30 s, 51˚C/30 s, 68 C/ 2 min 30 s/30 cycles on 95˚C/30 s, 55˚C/30 s and 68˚C/2 min 30 s, followed by a final extension at 68˚C for 7 min. Five microlitres of the reaction mixture from the first PCR was used as a template in the second round of nested PCR. The cycling conditions were identical for three genes: denaturation at 95 C for 5 min/10 cycles on 95 C/30 s, 52 C/ 30 s, 68 C/1 min 20 s/30 cycles on 95 C/30 s, 54 C/30 s, 68 C/1 min 20 s and the final extension at 68 C for 7 min.
Two reaction mixtures with different primer pairs were used for each gene in the second round of nested PCR. For the HN gene, the first primer pair was HN1 6784 F/HN1 7882 R, and the second pair was HN2 7678 F/HN2 8803 R. The first primer pair for the F gene was F1 4735 F/F1 5892 R, while the second pair was F2 5725 F/F2 6950 R. For the P gene reamplification, the first primer pair was P1 1671 F/P1 2900 R, and the second primer pair was P2 2694 F/P2 3737 R.
PCR samples were analysed by electrophoresis on 1.0 % agarose gel, and amplified products were cut out and purified. Purified PCR products were submitted to sequencing reaction with a Big Dye Terminator v3.1 Cycle Sequencing kit and primers used in a second round of the nested PCR. The nucleotide sequence was determined with an automated DNA sequencer ABI PRISM 3130 Genetic Analyzer (Applied Biosystems).
Primers used in amplification and sequencing reactions are presented in Table S1 (available in the online Supplementary Material). All alignments were performed using ClustalX 2.1 software. Selection of the best-fit models of nucleotide substitution was determined by jModelTest 2.1.4 software (Darriba et al., 2012) , and phylogenetic trees of the HN, F and P genes were generated using the maximum likelihood method by Molecular Evolutionary Genetics Analyses (MEGA) software, version 5.05. Bootstrap probabilities for 1000 iterations were calculated to evaluate confidence estimates (Guindon & Gascuel, 2003) .
Software DnaSP version 5.0 (Librado & Rosaz, 2009 ) was applied for analysis of nucleotide sequence data variability.
Deduced amino acid sequences and glycosylation site analysis
Deduced amino acid sequences of the HN, F and P/C genes were generated by translating nucleotide sequences with the standard genetic code using MEGA software. Potential N-and O-glycosylation sites were predicted by the NetNGlyc 1.0 and NetOGlyc 4.0 servers.
RESULTS

Clinical sample pool
This study involves 54 clinical samples positive in the DFA test for HPIV1 antigen and collected from hospitalized children during four consecutive years (January 2011 -December 2014 . In this period, the incidence of DFA-positive HPIV ( Our data indicated biennial occurrence of the HPIV1 epidemic seasons, beginning in the autumn of the odd years ( Fig. 1) . The leading cause for hospitalization of the patients from this study was upper respiratory infection (URI) (37 %; 20/54 samples), while diseases such as laryngitis, bronchiolitis and pneumonia appeared in equal proportion: 18.5 %, 12.9 % and 14.8 %, respectively. Other symptoms such as angina erythema and status febrilis appeared in 16.6 % of infected children.
Molecular detection of HPIV1
Thirty-one clinical samples from the hospitalized patients were analysed by RT-PCR for the HPIV1 HN gene.
Twenty-six out of the 31 samples analysed were PCR positive, but four positive samples had PCR products that are too weak for sequencing analysis; therefore, 22 samples were included for further analyses (Table 1) . Fifteen RT-PCR-positive samples were from the first epidemic season (September 2011 -February 2012 , one from the second in September 2012 and six from the third season (October 2013-January 2014) ( Fig. 1 ). Five samples, although strongly positive in DFA testing, were PCR negative. It is assumed that the reason for negative or weakly positive samples lies in inadequate storage conditions, which potentially damaged the viral particle and resulted in the degradation of the viral RNA.
Phylogenetic analysis of HPIV1 HN gene
We combined our data with the previously published HN gene sequences collected in the USA, France, Mexico and Thailand over a period of 49 years to generate the HN phylogenetic tree (Fig. 2a) .
A total of 43 HN gene sequences (cds region; 1728 nt) were aligned; 21 sequences previously deposited in GenBank with 22 sequences were obtained in this study. Three sequences from this study were identical in HN gene coding region: KT336333, KT336336 and KT336339, respectively; sequence KT336333 was used for further analysis. Three major branches were identified in the phylogenetic tree generated from HN sequences, which correspond to clades I, II and III in a phylogenetic tree of the HPIV1 whole viral genomes reported by Beck et al. (2012 
Phylogenetic analysis of HPIV1 F and P/C genes
Thirteen clinical samples from this study, along with the 19 samples from GenBank were selected to generate phylogenetic trees of F and P/C genes (Fig. 2b, c and Table 1 ). The clinical samples from this study were chosen based on the topology of the HN gene phylogenetic tree; seven of them were from clade III and six from clade II (F gene 11 samples: KT992797-KT992807; P/C gene 12 samples: KU050084-KU050095). Both generated trees confirmed the observed HN topology; therefore, representative samples from this study were grouped to the same clade as in the HN phylogenetic tree.
Analysis of nucleotide sequence variability
The diversity of nucleotide sequences generated in this study was calculated for P/C, F and HN genes, using DNASp 5.10 software. The total number of analysed nucleotide sequences from this study was 12 for P/C gene, 11 for F gene and 22 for HN gene, respectively. The nucleotide diversity (p), ratio of non-synonymous (Ka) to synonymous (Ks) mutation (Ka/Ks) and average number of nucleotide differences are summarized in Table S2 .
Three genes have a relatively similar nucleotide diversity (p) of the entire gene: P/C 0.0255, F 0.0236 and HN 0.0237. The highest nucleotide diversity was observed for the P gene coding region, while F gene had the lowest p value. The largest difference between the analysed genes was seen when the Ka/Ks ratio was calculated. The coding region of the F gene had a Ka/Ks ratio of 0.0635, while the rest of ORFs had values similar to one another (0.2143 for P, 0.1958 for C and 0.2073 for HN). These data suggest similar rates of nucleotide alteration throughout the entire part of the analysed HPIV1 genomes but emphasize that nucleotide changes in the F ORF are more of a synonymous type (Ks) than those in the P/C or HN ORF. This implies a conserved nature for the F ORF.
The average nucleotide diversity of non-coding region (NCR) is 0.02 (range 0.0194-0.0259), with the exception of the F gene 5¢NCR (p=0.0528) and NCRs of the HN gene (p=0.0424 of 5¢NCR; p=0.0524 of 3¢NCR), which are the most divergent regions. Two samples from our study (KT336335 and KT336347) have a six nucleotide extension (AAAAGA) in the 5¢NCR F region (nt 119-124), which was also found in two HPIV1 strains in GenBank (accession nos JQ902004 and KF687314).
Amino acid sequence diversity
Further analysis of the Croatian HPIV1 samples included analysis of amino acid diversity calculated with MEGA software 5.0. The lowest number of substitutions was observed for the F protein (14/555, 2.52 %), while C and HN proteins have similar substitution numbers: 14/204 (6.86 %) and 39/ 575 (6.78 %), respectively. The highest number of substitutions was detected in the P protein (49/568, 8.62 %) (Table S2 ). Clade-specific substitution was detected in 35-48 % of all amino acid substitutions per protein: in P protein 21 (42.8 %) of 49, in C protein 5 (35.7 %) of 14, in F 5 (38.4 %) of 13 and in HN 18 (46.1 %) of 39.
The P protein consists of N-proximal and C-terminal functional domains. The first part of the N-proximal domain was defined to function in RNA assembly, in experiments conducted by deletion of aa 33-41 and aa 1-77 of Sendai virus (SeV) (Curran & Kolakofsky, 1988; Karron & Collins, 2013) . The second part of the N-proximal domain (aa 78-324) is apparently dispensable for genome RNA synthesis and assembly (Lamb & Parks, 2013) . The second functional domain, the C-terminal region (aa 325-568), contains domains for multimerization of P protein, two regions for interactions with L protein (residues 387-423 and 511-568 assigned for P of HPIV1) (Bousse et al., 2001) and two regions for stable binding to the nucleocapsid (residues 345-412 and 479-568/540-568 assigned for P of SeV) (Curran & Kolakofsky, 1988; Ryan et al.,1990) . Region 540-568 is also necessary for transcription (Karron & Collins, 2013) .
The amino acid diversity calculated for 12 P proteins obtained in this study and expressed as the ratio of substitutions per residue established 0.132 diversity for the N-proximal domain and 0.024 diversity for the C-terminal domain, respectively. The first and second parts of the N-proximal domain have similar amino acid diversity; residues 1-77 have 0.132 substitution per residue, and the second part (residues 78-324) has 0.133 diversity (Table S2 ).
In the C-terminal part of P protein, one out of two domains responsible for P:L interaction (aa 511-568) has a substitution of aa 534 which is a specific feature of the clades (Ala for samples of clade II and Val for samples of clade III).
Binding domain for P:NP:RNA (aa 540-568) is completely conserved across all samples analysed. F protein is expressed as a precursor F0, which forms a disulphide-bonded structure upon cleavage by cellular proteases. The mature form consists of subunits F1 and F2. The F2 subunit carries a signal peptide on its N-terminus, while the F1 subunit consists of fusion peptide on its N-terminus, followed by ectodomain (composed of two heptad repeat regions, HRR), transmembrane domain and a C-terminal cytoplasmic domain (Lamb & Parks, 2013) . For assignment of F protein domain positions, the following steps were implemented: data were obtained from Phobius program (EMBL-EBI; Phobius), alignment of SeV (GenBank M30202) and HPIV1 F proteins, together with the data of the previously determined SeV functional domain (Fouillot-Coriou & Roux, 2000) . In HPIV1 F protein, we predicted these positions: signal peptide from aa 1-22, the remaining part of F2 from aa 23-106, cleavage site of F0 from aa 107 to 112 (dnpqtr#f), fusion peptide from aa 113 to 138, ectodomain with two HRRs from aa 139 to 497, transmembrane region from aa 498 to 519 and cytoplasmic domain from aa 520 to 555, respectively. Analysis of these separate F protein regions established 3 aa diversity in the signal peptide (ratio of substitution per residue 0.136), one alternative position in the remaining part of F2 (0.011), 6 aa alternative positions in the two HRRs (0.016), two alternative positions in the transmembrane domain (0.090) and two in the cytoplasmic domain (0.055), for the 11 F proteins from this study. These data show that the signal peptide is the most divergent part of F protein, while the remaining part of F is highly conserved.
The HN protein has seven functionally different domains (Beck et al., 2012; Henrickson & Savatski, 1997) . The amino acid diversity between them is expressed as the ratio of substitutions per residue: 0.257 in the cytoplasmic domain (aa residues 1-35), 0.160 in the transmembrane region (aa 36-60), 0.025 in the stalk domain (aa 61-191), 0.033 in the high structural homology I region (aa 192-341), 0.086 in the non-structural assignment (aa 342-457), 0.021 in the high structural homology II region (aa 458-504) and 0.070 in the carboxyl domain (aa 505-575), respectively. The cytoplasmic domain showed the highest amino acid diversity, while high structural domain II was the most conserved within the Croatian HN proteins.
Analysis of potential glycosylation sites
Potential glycosylation sites of HPIV1 surface proteins, F and HN, have not so far been described in the literature. Potential N-and O-glycosylated sites in Croatian F and HN protein sequences were determined using NetNGlyc 1.0 and NetOGlyc 4.0 servers (Steentoft et al., 2013) .
Five potential N-glycosylation sites were conserved for all F proteins analysed (aa positions 100, 241, 529, 532 and 552). Analysis of O-glycosylated sites of F protein sequences deposited in GenBank showed extensive glycosylation in six parts: first 102, 105; second 207, 211, 215; third 223/ 399, 409; fourth 453; fifth 485 and sixth 495. Only one Croatian strain, HR/8.12 (2000) , exhibited this glycosylation pattern, while the other samples from this study had considerably lower number of potentially O-glycosylated sites (positions 102, 103 and 453).
We identified that seven potential N-glycosylation sites are conserved among all the HN proteins used in this study. Potential N-glycosylation sites are at aa positions 19, 77, 173, 277, 361, 449 and 551. Amino acid positions from 1 to 60 belong to cytoplasmic and transmembrane domains, respectively, and are not expected to be glycosylated.
Samples belonging to clade II have only the conserved seven N-glycosylated sites, except for the strain HR/50.13 (1833), which has one additional site predicted to be N-glycosylated at position 18. Strains belonging to clade III have nine potential N-glycosylation sites: seven shared with clade II strains and two clade-specific sites at aa 448 and 511, respectively. A unique N-glycosylation pattern was observed for strains belonging to clade I (JQ901979 and JQ901972), one strain from clade II (JQ901979) and strain U709936, respectively; all of these strains have eight potentially glycosylated residues: seven conserved sites, along with a clade-III-specific site at residue 511. Two strains isolated in 1991 (U01074) and 1964 (AF457102) have ten potential N-glycosylation sites: eight common with strains belonging to clade I and the two additional ones at residues 8 and 499, respectively. These data suggested that HN protein is abundantly glycosylated with N-linked sugar moieties and that the specific N-glycosylation pattern could distinguish between clades II and III.
Potential O-glycosylated sites are also very abundant in the HN protein of all analysed samples. There are five potential regions of HN with O-glycosylation potential: first 72, 74, 75, 79; second 181, 184, 187; third 272; fourth 493, 494, 495, 500, 501 ; fifth 511. Clade II had a unique O-glycosylated site at residue 511, while specific sites for clade III were at positions 72 and 494.
DISCUSSION
HPIV1 is a causative agent of respiratory illness with the potential to cause severe diseases of upper and lower respiratory tract. In this study, we analysed 22 clinical samples from children in Croatia infected with HPIV1 in the period from September 2011 to January 2014. The age of patients was in the range from 2 months to 7 years, with 85 % of patients younger than the age of 3 years.
Our sample pool reflected the strong seasonal occurrence of HPIV1; incidence of infection had a peak in autumn and winter months (September-February). Although our samples originate from a short period of time (September 2011-January 2014), they distinctly indicate biennial occurrence of HPIV1, as we previously found for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in Croatia (Ljubin-Sternak et al., 2014; Mlinarić -Galinovic et al., 2012) . Biennial circulation of HPIV1 has also been reported in previous epidemiological studies (Fry et al., 2006; Morgan et al., 2013; Villaran et al., 2014; Wang et al., 2015) . Molecular characterization (detection, genotype assignment and evolution of specific gene regions) of HPIV1 from different geographical areas could aid the development of an efficient vaccine or therapy.
Genotyping of HPIV1 is not specified regarding the specific part of the genome, as it is for some other paramyxoviruses. For instance, a part of the G protein of RSV is used for genotype-based studies; a part of F gene for HMPV studies; the entire SH gene for mumps virus; and the terminal fragment of N gene for measles virus, respectively (Jin et al., 2015; Martinelli et al. 2014; Nor'e et al., 2014; WHO, 2012) . Small volumes of clinical samples and limitations of the classical sequencing method imposed a reason to arbitrarily determine the region for genotyping our samples. HN gene, encoding for viral surface glycoprotein, was the main object for HPIV1 genotyping in the literature (Beck et al., 2012; Henrickson & Savatski, 1997; Mizuta et al., 2011) . Furthermore, HPIV1 GenBank sequences comprise mainly HN gene sequences. Phylogenetic trees generated with Croatian HN gene sequences distinctly allocate samples from this study in two branches, annotated by Beck et al. (2012) as clades II and III. F gene and P gene phylogenetic trees confirmed clade topology of our samples and drew attention to other segments of the HPIV1 genome suitable for genotyping. The P gene coding region from 30 analysed samples and especially the P gene nucleotide fragment from 800 to 1100 nt (p=0.042) (data not shown) were the most variable parts of partially analysed HPIV1 genomes in this study. Therefore, they are suitable as objects for further phylogenetic analysis (genotyping).
Literature data showed that substitution of one amino acid in HPIV1 proteins could significantly influence their biological features (Bartlett et al., 2007; Bousse et al., 1995 Bousse et al., , 2006 Takaguchi et al., 2011) .
Although the cytoplasmic tails of glycoproteins F and HN are not exposed on the outer site of the viral envelope and have no influence on the immune response of the host cell, their impact is evident in the process of assembling of paramyxovirus viral particles (Shevtsova-Horoz et al., 2015; Stone et al., 2013; Takimoto et al., 1998) . The conserved part of HN cytoplasmic tail SYWST was identified as required for specific incorporation of HN proteins into progeny SeV (Takimoto et al., 1998) and was possibly responsible for interaction with SeV and HPIV1 M protein.
We have identified a change in this conserved region in one of our samples (HR/3.12 (1022), KT336342) where the first aa Ser has changed to Pro (SYWST changed into PYWST) which could influence HN incorporation in virus particles. Literature data confirmed lower HN incorporation in virion particles as a result of mutation in the SYWST region (Fouillot-Coriou et al., 2000) .
The cytoplasmic tail of HPIV1 F protein is important for the accumulation of structural viral components at the plasma membrane assembly sites (Stone et al., 2013) . Some parts of the cytoplasmic tail are strongly conserved, such as region TYTLE (Stone et al., 2013) /AYTLE (our HPIV1 analysis, data not shown) and seven additional amino acids. Our analysed samples have two amino acid positions (aa 526 and aa 546) in the F cytoplasmic tail which differ from consensus sequence and are specific for clade III lineage. The impact of these changes on the accumulation of structural viral components has yet to be discovered.
Glycosylation of surface proteins is a presumed mechanism for helping virus to evade the host immune response (Palomo et al., 1991 (Palomo et al., , 2000 Sommerstein et al., 2015; Suptawiwat et al., 2015) . Variation in the number of specific glycosylation sites can influence the expression of viral protein epitopes and, consequently, the type of produced specific antibodies. Alternatively, it can also circumvent virus neutralization by pre-existing antibodies.
Here, we presented evidence that HPIV1 HN proteins have specific N-glycosylation and O-glycosylation patterns depending on the clade specification. Further analysis is necessary to prove the functional importance of different patterns in HPIV1 HN glycosylation. This information could be useful to predict the influence of possible glycosylation site changes on viral virulence and immune responses in HPIV1 vaccine design.
The F protein of the majority of Croatian strains utilized only two potential O-glycosylated sites, compared with an average of six potential sites observed for strains deposited in GenBank. Differences in usage of the potential sites as acceptors for sugars could influence exposure to the host immune system or binding of F and HN proteins, during attachment and fusion processes.
Previously published data (Bousse et al., 2002) indicated that the long 5¢NCR of the HPIV1 F gene, in addition to the intergenic and transcriptional start signals at the M-F junction, affects the transcriptional termination of the M and F genes and increased production of read-through transcripts of the M-F. This failure also affects reduction of F protein synthesis and virus production (Bousse et al., 2002) . Abbreviation of most of 5¢NCR resulted in efficient termination of the transcripts (Bousse et al., 2002) . The prolonged 5¢NCR F region detected in four samples belonging to clade III (two from this study and two from sequences deposited in GenBank) has the potential for production of even more read-through M-F transcripts than the 5¢NCR F region of conventional length of 264 nt. This assumption remains to be elucidated in further study. Our results confirmed co-circulation of distinct HPIV1 viruses belonging to clades II and III demonstrated in recent evolutionary studies by Beck et al. (2012) and Mizuta et al. (2011) . We believe that these data draw attention on the fact that the HPIV1 viral population does not imply geographically restricted strains. In addition, the results from this study contribute to better knowledge of the molecular epidemiology of HPIV1 virus in Eastern Europe and provide data for a further comparative analysis with other HPIV1 viruses circulating in other regions of the world.
